= Emerging. More than 5 years before clinical availability. (16.60%, 2024)
= Expected to be clinically available in 1 to 4 years. (37.02%, 2024)
= Clinically available now. (46.38%, 2024)
MSACL 2024 : Session

MSACL 2024 Abstract

Self-Classified Topic Area(s): Imaging > Imaging
Podium Presentation in De Anza 1 on Thursday at 14:10 (Chair: Erin Seeley / Jessica Moore)

Discussion on the Pros and Cons of Working with Fresh Frozen versus FFPE Tissue

Discussion Session (Presenter)

Abstract

Session Discussion.

Financial Disclosure

DescriptionY/NSource
Grantsno
Salaryno
Board Memberno
Stockno
Expensesno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above:

no